Cellipont Bioservices Partners with Adva Biotechnology for Advanced Cell Therapy Manufacturing

• Cellipont Bioservices, a cell therapy CDMO, partners with Adva Biotechnology to leverage the ADVA X3 platform in North America.

• The ADVA X3 system is designed to simplify and accelerate the manufacturing of CAR-T therapies from manual to fully automated and cGMP in as little as three months.

Cellipont Bioservices, a cell therapy Contract Development and Manufacturing Organisation (CDMO), has announced a strategic partnership with Adva Biotechnology, an Israel-based private biotech company. The collaboration will see Cellipont leverage Adva Biotechnology’s ADVA X3 platform in North America, a move set to revolutionise the manufacturing of advanced cell therapies.

The ADVA X3 is an advanced, fully automated platform designed to streamline processes and reduce costs in the manufacturing of cell therapies. It aims to simplify and accelerate the production of CAR-T therapies, transitioning from manual to fully automated and cGMP in as little as three months. This advancement is expected to make these therapies more accessible to a broader patient population.

The partnership combines Cellipont’s process and manufacturing expertise and purpose-built facility with the ADVA X3 metabolic sensing-based AI-driven automated manufacturing platform. This combination allows therapy developers to quickly transition from manual processing to fully automated and cGMP. The ADVA X3 system supports a range of cell therapies such as NK, TCR, TIL and exosomes from activation to the final cell product.

“We’re proud to partner with Adva Biotechnology and be the first CDMO in North America to offer the ADVA X3 to clients. The ADVA X3’s automation and precision are game changers, enabling us to scale up production and meet the urgent needs of patients,” said Michael O’Mara, COO of Cellipont Bioservices.

Dr. Ohad Karnieli, CEO of Adva Biotechnology, echoed these sentiments, stating, “The collaboration with Cellipont Bioservices is a pivotal moment for us. The ADVA X3 embodies our commitment to innovation and patient care, and with Cellipont’s expertise, we’re set to transform the landscape of cell therapies.”